Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Syndax Pharmaceuticals Inc.
Headquarters: Waltham, MA, United States of America
Website: http://www.syndax.com
Year Founded: 2005
Status: Public
Industry Sector: HealthTechnology
CEO: Michael A. Metzger, MBA
Number Of Employees: 270
Enterprise Value: $904,778,699
PE Ratio: -3.02
Exchange/Ticker 1: NASDAQ:SNDX
Exchange/Ticker 2: N/A
Latest Market Cap: $1,071,864,000
BioCentury | Nov 26, 2024
Deals
Kyowa Kirin brings global reach to Kura’s menin program via licensing deal
Also in BioCentury’s Deals Report: Novartis buys gene therapy play Kate, Telix buys FAP-targeting theranostics, and more
BioCentury | Nov 13, 2024
Product Development
Adverse event casts shadow over Neurogene’s Rett syndrome readout
BioCentury’s Clinical Report also analyzes data from Syndax and Gan & Lee, plus pipeline updates from Sarepta, Tango and RAPT
BioCentury | Mar 19, 2024
Management Tracks
Syndax names new commercial head
Plus: Everest hires Sandra Zeng as CMO and Rico Liang as chief product officer, and updates from Parexel, Dignify and GRO
BioCentury | Dec 16, 2023
Finance
Dec. 15 Quick Takes: Pfizer, Nona in ADC deal
Plus: FDA approves Padcev/Keytruda for 1L advanced urothelial cancer, obesity play Fractyl files for IPO and updates from Merck, Syndax, AC Immune, BMS
BioCentury | Oct 2, 2023
Regulation
Oct. 2 Quick Takes: Takeda withdrawing Exkivity after confirmatory miss
Plus: Novartis’ iptacopan shows benefit in IgA nephropathy and updates from Mirum, Lexeo, Rocket, Lilly, Syndax, SAB, Amicus and Pneumagen
BioCentury | Jul 25, 2023
Product Development
July 24 Quick Takes: Kodiak sinks on tarcocimab DME miss
Plus: BMS takes stake in Immatics and updates from Syndax, Incyte, Crescendo, Bavarian Nordic, Horizon, CERSI
BioCentury | Mar 31, 2023
Management Tracks
Amarin CEO Mikhail resigns, Kostas named chair
Plus: BioCryst appoints Hutson chair and updates from Flare, Mytide and TScan
BioCentury | Dec 2, 2022
Management Tracks
Wessman to be CEO at Alvotech
Plus: Sabus goes to Syndax and updates from SciNeuro, Sapience and BillionToOne
BioCentury | Jul 21, 2022
Finance
July 20 Quick Takes: Multiomics-driven cancer newco Auron raises $48M series A
Plus Section 32 leads BigHat’s $75M round; PTC gains first global approval of brain-infused gene therapy; and more
BioCentury | Jun 14, 2022
Management Tracks
McCracken named CEO at Evonetix
Plus Pirzkall becomes CMO at Asher, and updates from Domain, Syndax,
Items per page:
1 - 10 of 139